Annals of Surgical Oncology

, Volume 13, Issue 6, pp 887–898 | Cite as

Current Issues in Adjuvant Treatment of Stage II Colon Cancer

  • Thierry André
  • Daniel Sargent
  • Josep Tabernero
  • Michael O’Connell
  • Marc Buyse
  • Alberto Sobrero
  • Jean-Louis Misset
  • Corrado Boni
  • Aimery de Gramont
Review

Abstract

Background

Adjuvant chemotherapy with 5-fluorouracil modulated by folinic acid, combined with oxaliplatin, has now become an accepted standard of care for patients with stage III colon cancer. In contrast, the use of adjuvant therapy for stage II patients remains controversial, and the identification of reliable prognostic factors to aid therapeutic decision making is crucial.

Methods

The authors critically review the results of clinical trials and meta-analyses investigating the value of adjuvant chemotherapy for stage II patients, emphasizing the heterogeneous nature of this population and the difficulty of performing clinical trials with sufficient power to reliably assess treatment efficacy. They also discuss the evidence concerning potential prognostic factors, particularly molecular markers.

Results

Available clinical trial data do not support the routine use of adjuvant chemotherapy for all stage II patients but suggest that it should be considered, particularly for certain high-risk patients. Recent guidelines advocate considering factors such as tumor differentiation, tumor perforation, number of lymph nodes examined, and T stage when assessing the likely benefit:risk ratio. Microsatellite instability and allelic imbalance seem to be strong predictors of good and poor prognosis, respectively, and in the near future, therapeutic decision-making models are likely to be further refined by the inclusion of such molecular markers.

Conclusions

There is growing evidence that the prognosis of certain stage II patients with unfavorable prognostic factors can be improved by adjuvant chemotherapy, and increasingly refined tools are now available to define those most likely to benefit. Referral of stage II patients for individual assessment is strongly recommended.

Keywords

Colon cancer, stage II Adjuvant chemotherapy 5-Fluorouracil Leucovorin Oxaliplatin 

Notes

Acknowledgments

This article was derived from discussions at a meeting on adjuvant therapy of colon cancer organized by Aimery de Gramont, with financial support from Sanofi-Synthelabo, in September 2003. The authors thank Paula Harry (MediBridge, France) for medical writing support.

References

  1. 1.
    Advanced Colorectal Cancer Meta-analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10:896–903Google Scholar
  2. 2.
    Levi F, Misset JL, Brienza S, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 1992; 69:893–900PubMedGoogle Scholar
  3. 3.
    Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18:136–47PubMedGoogle Scholar
  4. 4.
    De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938–47PubMedGoogle Scholar
  5. 5.
    Tournigand C, André T, Louvet C, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229–37CrossRefPubMedGoogle Scholar
  6. 6.
    Grothey A, Deschler B, Kroening H, et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs. weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC) (abstract 512). Proc Am Soc Clin Oncol 2002; 21:129aGoogle Scholar
  7. 7.
    Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23–30CrossRefPubMedGoogle Scholar
  8. 8.
    Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335–42CrossRefPubMedGoogle Scholar
  9. 9.
    Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337–45CrossRefPubMedGoogle Scholar
  10. 10.
    Datamonitor. Treatment Algorithms: Colorectal Cancer 5th Edition—New Gold Standards Emerge but Unmet Need Remains. 2003. Available at: http://www.datamonitor.com/∼5316ab639141457fb1e7238dae8507c9∼/industries/research/?pid=DMHC1816&type=Report. Accessed: June 21, 2005
  11. 11.
    Van Cutsem E, Dicato M, Wils J, et al. Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001). Eur J Cancer 2002; 38:1429–36CrossRefPubMedGoogle Scholar
  12. 12.
    Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 2000; 88:1739–57CrossRefPubMedGoogle Scholar
  13. 13.
    Buyse M, Piedbois P. Should Dukes’ B patients receive adjuvant therapy? A statistical perspective. Semin Oncol 2001; 28(Suppl 1):20–4CrossRefPubMedGoogle Scholar
  14. 14.
    Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant chemotherapy of resected colon carcinoma. N Engl J Med 1990; 322:352–8PubMedCrossRefGoogle Scholar
  15. 15.
    International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345:939–44CrossRefGoogle Scholar
  16. 16.
    O’Connell MJ, Laurie JA, Kahn M, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998; 16:295–300PubMedGoogle Scholar
  17. 17.
    Haller DG, Catalano PJ, MacDonald JS, Mayer RJ. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: five-year report of INT-0089 (abstract 982). Proc Am Soc Clin Oncol 1998; 17:256aGoogle Scholar
  18. 18.
    Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999; 17:3553–9PubMedGoogle Scholar
  19. 19.
    Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, 5-fluorouracil and leucovorin as adjuvant treatment of colon cancer: results of the international randomized MOSAIC trial. N Engl J Med 2004; 350:2343–51CrossRefPubMedGoogle Scholar
  20. 20.
    Wolmark N, Wieand HS, Kuebler JP, Colangelo L, Smith RE. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP protocol C07 (abstract 3500). J Clin Oncol 2005; 23(16 Suppl; Pt 2 of 2):1092sGoogle Scholar
  21. 21.
    Mamounas E, Wieand S, Wolmark N, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B vs. Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999; 17:1349–55PubMedGoogle Scholar
  22. 22.
    International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 1999; 17:1356–63Google Scholar
  23. 23.
    Liver Infusion Meta-Analysis Group. Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. J Natl Cancer Inst 1997; 89:497–505CrossRefGoogle Scholar
  24. 24.
    Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004; 22:1797–806CrossRefPubMedGoogle Scholar
  25. 25.
    Adjuvant systemic therapy tools. Available at: http://www.mayoclinic.com/calcs. Accessed: June 21, 2005
  26. 26.
    Figueredo A, Germond C, Maroun J, Browman G, Walker-Dilks C, Wong S. Adjuvant therapy for stage II colon cancer after complete resection. Provincial Gastrointestinal Disease Site Group. Cancer Prev Control 1997; 1:379–92PubMedGoogle Scholar
  27. 27.
    Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in Evidence-Based Care’s Gastrointestinal Cancer Disease Site Group. J Clin Oncol 2004; 22:3395–407CrossRefPubMedGoogle Scholar
  28. 28.
    Meta-Analysis Group of the Japanese Society for Cancer of the Colon and Rectum and the Meta-Analysis Group in Cancer. Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol 2004; 22:484–92Google Scholar
  29. 29.
    Taal BG, Van Tinteren H, Zoetmulder FAN, et al. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer 2001; 85:1437–43CrossRefPubMedGoogle Scholar
  30. 30.
    Gray RG, Barnwell J, Hills R, et al. QUASAR: a randomized study of adjuvant chemotherapy (CT) vs. observation including 3238 colorectal cancer patients (abstract 3501). Proc Am Soc Clin Oncol 2004; 23:246Google Scholar
  31. 31.
    Schrag D, Rifas-Shiman S, Saltz L, Bach PB, Begg CB. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 2002; 20:3999–4005CrossRefPubMedGoogle Scholar
  32. 32.
    Cassidy J, Scheithauer W, McKendrick J, et al. Capecitabine (X) vs. bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): efficacy results of a phase III trial (abstract 3509). J Clin Oncol 2004; 22(14 Suppl):315sGoogle Scholar
  33. 33.
    Wolmark N, Wieand S, Lembersky B, Colangelo L, Smith R, Pazdur R. A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: results of NSABP Protocol C-06 (abstract 3508). J Clin Oncol 2004; 22(14 Suppl):315sGoogle Scholar
  34. 34.
    Hickish T, Boni C, Navarro M, et al. Stage II patients in the “MOSAIC” trial evaluating oxaliplatin/5FU/LV as adjuvant treatment of colon cancer: a subpopulation analysis (abstract 284P). Ann Oncol 2004; 15(Suppl 3):iii76Google Scholar
  35. 35.
    Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345:1091–7CrossRefPubMedGoogle Scholar
  36. 36.
    Petersen VC, Baxter KJ, Love SB, Shepherd NA. Identification of objective pathological prognostic determinants and models of prognosis in Dukes’ B colon cancer. Gut 2002; 51:65–9CrossRefPubMedGoogle Scholar
  37. 37.
    Merkel S, Wein A, Günther K, Papadopoulos T, Hohenberger W, Hermanek P. High-risk groups of patients with stage II colon carcinoma. Cancer 2001; 92:1435–43CrossRefPubMedGoogle Scholar
  38. 38.
    AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag, 2002Google Scholar
  39. 39.
    O’Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96:1420–5PubMedCrossRefGoogle Scholar
  40. 40.
    Le Voyer TE, Sigurdson ER, Hanlon AL, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of Intergroup Trial INT-0089. J Clin Oncol 2003; 21:2912–9CrossRefPubMedGoogle Scholar
  41. 41.
    Bukholm IR, Bondi J, Wiik P, et al. Presence of isolated tumor cells in mesenteric lymph nodes predicts poor prognosis in patients with stage II colon cancer. Eur J Surg Oncol 2003; 29:862–6CrossRefPubMedGoogle Scholar
  42. 42.
    Fielding LP, Arsenault PA, Chaphuis PH, et al. Clinicopathological staging for colorectal cancer: an International Documentation System (IDS) and an International Comprehensive Anatomical Terminology (ICAT). J Gastroenterol Hepatol 1991; 6:325–44PubMedGoogle Scholar
  43. 43.
    Maurel J, Launoy G, Grosclaude P, et al. Lymph node harvest reporting in patients with carcinoma of the large bowel: a French population-based study. Cancer 1998; 82:1482–6CrossRefPubMedGoogle Scholar
  44. 44.
    Goldstein NS, Weldon S, Coffey M, Layfield LJ. Lymph node recovery from colorectal resection specimens removed for adenocarcinoma: trends over time and a recommendation for a minimum number of lymph nodes to be removed. Am J Clin Pathol 1996; 106:209–16PubMedGoogle Scholar
  45. 45.
    Wong JH, Severino R, Honnebier MB, Tom P, Namiki TS. Number of nodes examined and staging accuracy in colorectal carcinoma. J Clin Oncol 1999; 17:2896–900PubMedGoogle Scholar
  46. 46.
    Benson AB, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22:3408–19CrossRefPubMedGoogle Scholar
  47. 47.
    Zaniboni A, Labianca R, for the Gruppo Italiano per lo Studio e la Cura dei Tumori del Digerente. Adjuvant therapy for stage II colon cancer: an elephant in the living room? Ann Oncol 2004; 15:1310–8CrossRefPubMedGoogle Scholar
  48. 48.
    Saha S, Dan AG, Beutler T, et al. Sentinel lymph node mapping technique in colon cancer. Semin Oncol 2004; 31:374–81CrossRefPubMedGoogle Scholar
  49. 49.
    Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993; 260:816–9PubMedGoogle Scholar
  50. 50.
    Halling KC, French AJ, McDonnell SK, et al. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 1999; 91:1295–303CrossRefPubMedGoogle Scholar
  51. 51.
    Parc Y, Gueroult S, Mourra N, et al. Prognostic significance of microsatellite instability determined by immunohistochemical staining of MSH2 and MLH1 in sporadic T3N0M0 colon cancer. Gut 2004; 53:371–5CrossRefPubMedGoogle Scholar
  52. 52.
    Carethers JM, Chauhan DP, Fink D, et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999; 117:123–31CrossRefPubMedGoogle Scholar
  53. 53.
    Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349:247–57CrossRefPubMedGoogle Scholar
  54. 54.
    Carethers JM, Smith EJ, Behling CA, et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 2004; 126:394–401CrossRefPubMedGoogle Scholar
  55. 55.
    Allegra CJ, Kim G, Kirsch IR. Microsatellite instability in colon cancer. N Engl J Med 2003; 349:1774–6CrossRefPubMedGoogle Scholar
  56. 56.
    Lanza G, Matteuzzi M, Gafá R, et al. Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. Int J Cancer 1998; 79:390–5CrossRefPubMedGoogle Scholar
  57. 57.
    Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001; 344:1196–206CrossRefPubMedGoogle Scholar
  58. 58.
    Zhou W, Goodman SN, Galizia G, et al. Counting alleles to predict recurrence of early-stage colorectal cancers. Lancet 2002; 359:219–25CrossRefPubMedGoogle Scholar
  59. 59.
    Kornmann M, Schwabe W, Sander S, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 2003; 9:4116–24PubMedGoogle Scholar
  60. 60.
    Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2004; 22:529–36CrossRefPubMedGoogle Scholar
  61. 61.
    Garrity MM, Burgart LJ, Mahoney MR, et al. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes’ B2 or C colon cancer: a North Central Cancer Treatment Group study. J Clin Oncol 2004; 22:1572–82CrossRefPubMedGoogle Scholar
  62. 62.
    Wang Y, Jatkoe T, Zhang Y, et al. Gene expression profiles and molecular markers to predict recurrence of Dukes’ B colon cancer. J Clin Oncol 2004; 22:1564–71CrossRefPubMedGoogle Scholar

Copyright information

© The Society of Surgical Oncology, Inc. 2006

Authors and Affiliations

  • Thierry André
    • 1
    • 2
    • 3
  • Daniel Sargent
    • 4
  • Josep Tabernero
    • 5
  • Michael O’Connell
    • 6
  • Marc Buyse
    • 7
  • Alberto Sobrero
    • 8
  • Jean-Louis Misset
    • 9
  • Corrado Boni
    • 10
  • Aimery de Gramont
    • 2
    • 3
    • 11
  1. 1.Service d’Oncologie MédicaleHôpital TenonParis Cedex 20France
  2. 2.CancerEst, Hôpital Saint AntoineParis Cedex 12France
  3. 3.GERCOR (Franch Oncology Research Group)ParisFrance
  4. 4.Mayo ClinicRochester
  5. 5.Vall d’Hebron University HospitalBarcelonaSpain
  6. 6.NSABP Foundation Research ProgramPittsburgh
  7. 7.IDDIBelgium
  8. 8.Ospedale S. MartinoGenovaItaly
  9. 9.Hôpital Saint-LouisParisFrance
  10. 10.Arcispedale S. Maria BuovaRegio EmiliaItaly
  11. 11.Hôpital Saint-AntoineParis Cedex 12France

Personalised recommendations